GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (OTCPK:MBCOF) » Definitions » Debt-to-Revenue

MBCOF (Marvel Biosciences) Debt-to-Revenue : N/A (As of Oct. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Marvel Biosciences Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Marvel Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2024 was $0.00 Mil. Marvel Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2024 was $1.24 Mil. Marvel Biosciences's annualized Revenue for the quarter that ended in Oct. 2024 was $0.00 Mil.

Marvel Biosciences Debt-to-Revenue Historical Data

The historical data trend for Marvel Biosciences's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marvel Biosciences Debt-to-Revenue Chart

Marvel Biosciences Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24
Debt-to-Revenue
N/A N/A N/A N/A N/A

Marvel Biosciences Quarterly Data
Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Marvel Biosciences's Debt-to-Revenue

For the Biotechnology subindustry, Marvel Biosciences's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marvel Biosciences's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marvel Biosciences's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Marvel Biosciences's Debt-to-Revenue falls into.


;
;

Marvel Biosciences Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Marvel Biosciences's Debt-to-Revenue for the fiscal year that ended in Jul. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 1.247) / N/A
=N/A

Marvel Biosciences's annualized Debt-to-Revenue for the quarter that ended in Oct. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 1.243) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Oct. 2024) Revenue data.

Marvel Biosciences Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Marvel Biosciences's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Marvel Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (OTCPK:MBCOF) » Definitions » Debt-to-Revenue
Comparable Companies
XCNQ:ASEP XCNQ:LOBE TSXV:QPT TSX:APLI XCNQ:RIZE TSXV:XRTX TSXV:IOT TSXV:IBO TSXV:CYTO XCNQ:NURL VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
MRVL:Canada
Address
505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2
Website
https://www.marvelbiotechnology.com
Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.